Notice of NCI Participation in PAR-22-064, "Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional)"
Notice Number:
NOT-CA-22-048

Key Dates

Release Date:

February 3, 2022

Related Announcements

PAR-22-064 - Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in Funding Opportunity Announcement (FOA) PAR-22-064,"Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional)".

The following sections of PAR-22-064 have been modified (see text added in bold italics) to highlight NCI’s participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute on Minority Health and Health Disparities (NIMHD)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute on Deafness and Other Communication Disorders (NIDCD)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Sexual and Gender Minority Research Office (SGMRO)

Office of Research on Women's Health (ORWH)

National Cancer Institute (NCI)

Assistance Listing Number(s)

93.307, 93.846, 93.173, 93.313, 93.393

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Other Participating Institutes/Centers/Offices Areas of Research Interest

The following paragraph has been added after Office for Research on Women's Health (ORWH)'s Areas of Research Interest

National Cancer Institute (NCI)

Division of Cancer Control & Population Sciences (DCCPS)

The mission of the NCI Division of Cancer Control & Population Sciences (DCCPS) is to reduce risk, incidence, and deaths from cancer as well as enhance the quality of life for cancer survivors. DCCPS is interested in supporting research that advances knowledge about factors influencing PCR and interventions that enhance PCR and outcomes related to cancer prevention, screening, diagnosis, treatment, and survivorship among populations that experience health disparities. Applications to DCCPS are encouraged to address intersections or interactions among factors at two or more levels (e.g., patient, caregiver, clinician, practice, health system, community, policy) relevant to patient-clinician relationships and related outcomes. DCCPS also includes genetic counselors in the definition of clinicians (See “key definitions” section). Research areas of interest to DCCPS include, but are not limited to, studies that:

  • Identify, develop, and/or test effective mechanisms that enhance PCR, alignment of care goals, and coordination of care over time, particularly among populations with multiple chronic conditions or limited continuity of care.
  • Test innovative interventions that promote clarity of roles, goals of care, shared decision-making, other aspects of patient and/or caregiver engagement, and communication among clinicians and people from populations that experience cancer health disparities.
  • Examine how empathy, trust, and other factors related to patient-clinician relationship affect patient and clinician expectations and communication about cancer prevention, screening, genetic risk, diagnosis, treatment, and survivorship.
  • Test interventions to promote patient-clinician communication regarding social risks (e.g., financial distress, food insecurity) as they relate to cancer prevention, screening, diagnosis, cancer treatment, and survivorship.
  • Address trust, communication, and vaccine uptake in areas of low HPV vaccine adherence; and evaluate or improve factors at multiple levels influencing parent/guardian-clinician conversations about youth HPV vaccination and associations with adherence rates
  • Examine how digital tools and technologies (e.g., telehealth, patient portals, wearable devices) influence the quality of patient-clinician communication and relationships.
  • Explore the impact of social media and/or health misinformation on patient-clinician communication and test strategies that address misinformation in the context of the patient-clinician relationship
  • Evaluate and intervene on discriminatory, biased, and/or stigmatizing policies, systems, structures, and processes that influence patient-clinician communication and contribute to cancer-related disparities.
  • Examine how concordance between patient and clinician identities (e.g., racial, ethnic, gender, cultural, spiritual) influence norms and expectations for verbal and nonverbal communication during patient-clinician interactions, the patient-clinician relationship, and subsequent cancer-related outcomes
  • Understand and test innovative interventions that address clinician, care team, practice, and/or health system factors that influence PCR and related outcomes.

Division of Cancer Prevention (DCP)

The NCI Division of Cancer Prevention (DCP) leads, supports, and promotes rigorous, innovative research and training to prevent cancer and its consequences, to improve the health of all people. DCP is interested in research that promotes communication, shared decision-making, and strengthens PCR to address cancer health disparities and improve outcomes related to cancer prevention, screening, cancer symptomatology, and treatment related toxicities along the cancer care continuum. DCP is also interested in innovative studies that enhance enrollment of underrepresented populations to NCI supported clinical trials with a focus on improved communication among patients, caregivers and clinicians and interdisciplinary teams and specialists; shared decision-making; and PCR.Research areas of interest to DCP include, but are not limited to, studies that:

  • Test innovative interventions to promote communication and shared decision-making between clinicians and people from populations that experience cancer health disparities in regard to palliative care, hospice care, and end of life care.
  • Evaluate modalities (handheld devices, web-based platforms, phone)that report cancer treatment toxicities and their impact on communication between clinicians and people from populations that experience cancer health disparities.
  • Evaluate the impact of accumulated stress, allostatic load, and social determinants of health on PCR and communication and its impact on cancer pain and symptom management.
  • Evaluate and intervene on discriminatory, biased, and/or stigmatizing policies, structures, and processes that impact assessment and management of cancer pain and access to pharmacological as well as nonpharmacological and behavioral interventions in people from populations that experience cancer health disparities.
  • Test interventions to promote patient/clinician communication regarding psychosocial issues (e.g., depression, anxiety) related to cancer diagnosis and cancer treatment in people from populations that experience cancer health disparities.
  • Test innovative interventions that reduce distrust of medical research and increase racial and ethnic minority participation in precision health including acquisition of biospecimens that will lead to earlier detection and treatment of cancer.
  • Test innovative interventions to improve PCR and patient/clinician communication regarding cancer symptom management, screening, and prevention clinical trial participation among people from populations that experience cancer health disparities.
  • Test innovative interventions to promote shared decision making among patients, families, caregivers, and clinicians to participate in symptom management, screening, and prevention clinical trials.
  • Evaluate the effects of PCR characteristics (including but not limited to duration of PCR, involvement of family members, clinician specialty, similar P-C race/ethnic background, clinician’s study role [e.g., research nurse, study coordinator, PI, attending physician]) on cancer symptom management, screening, and prevention clinical trial participation decisions, in people from populations that experience cancer health disparities.
  • Test innovative interventions to promote effective communication between clinicians and patients or potential clinical trial participants from populations that experience cancer health disparities regarding personal cancer risk factors and risks of adverse effects in cancer symptom management cancer prevention and screening clinical trials.
  • Test innovative approaches to promote and increase effective communication about cancer symptom management, screening, and prevention clinical trials among oncologists and primary care providers, and other specialists (gastroenterologists, pulmonologists, urologists, etc.) to improve clinical trial enrollment of participants from populations that experience cancer health disparities.
  • Develop models for oncologists and primary care providers to communicate and collaboratively manage people on clinical trials from populations that experience cancer health disparities and have multiple comorbidities.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Larissa Aviles-Santa, MD, MPH
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-827-6924
Email: avilessantal@nih.gov

Xincheng (Ted) Zheng, MD, PhD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-594-4953
E-mail: zhengx4@mail.nih.gov

Howard J. Hoffman
National Institute on Deafness and Other Communication Disorders (NIDCD)
Phone: 301-402-1843
E-mail: hoffmanh@ms.nidcd.nih.gov

Damiya Eve Whitaker
Office Of Research on Women's Health (ORWH)
Phone: 240-276-6170
E-mail: damiya.whitaker@nih.gov

Christopher Barnhart, PhD
Sexual & Gender Minority Research Office (SGMRO)
Telephone: 301-594-8983
Email: christopher.barnhart@nih.gov

Sallie J. Weaver, PhD MHS
National Cancer Institute (NCI)
Telephone: 240-276-6254
Email: sallie.weaver@nih.gov

Amanda Acevedo, PhD
National Cancer Institute (NCI)
Telephone: 240-276-5896
Email: amanda.acevedo@nih.gov

Diane St. Germain, RN, MS, CRNP
National Cancer Institute (NCI)
Telephone: 240-276-7050
Email: dstgermain@mail.nih.gov

Financial/Grants Management Contact(s)

Priscilla Grant, JD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8412
Email: grantp@mail.nih.gov

Erik Edgerton
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-594-7760
E-mail: erik.edgerton@nih.gov

Christopher Myers
National Institute on Deafness and Other Communication Disorders (NIDCD)
Phone: (301) 435-0713
E-mail: myersc@nih.gov

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Sallie J. Weaver, PhD, MHS
National Cancer Institute (NCI)
Telephone: 240-276-6254
Email: sallie.weaver@nih.gov